NexImmune, Inc.
NASDAQ:NEXI
Overview | Financials
Company Name | NexImmune, Inc. |
Symbol | NEXI |
Currency | USD |
Price | 0.201 |
Market Cap | 280,329 |
Dividend Yield | 0% |
52-week-range | 0.188 - 28.695 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Ms. Kristi Jones R.Ph. |
Website | https://www.neximmune.com |
An error occurred while fetching data.
About NexImmune, Inc.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD